Roth Capital’s healthcare analyst Joseph Pantginis came out with a few insights on Celator Pharmaceuticals Inc (NASDAQ:CPXX), after the company announced enrollment completion of the supporting PK/PD …
In a research note released this morning, Roth Capital reiterated coverage on Celator Pharmaceuticals, Inc (CPXX) with an Outperform rating and a price target of $15.00, which is based …
